Impact of Angiotensin II Receptor Blockers on Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005–2014)

Gwang Sil Kim, MD, PhD1, Young-Guk Ko, MD2, Yongsung Suh, MD, PhD3, Hoyoun Won, MD, PhD4, Sung-Jin Hong, MD2, Chul-Min Ahn, MD, PhD4, Jung-Sun Kim, MD, PhD2, Byeong-Keuk Kim, MD, PhD2, Donghoon Choi, MD, PhD2, Myeong-Ki Hong, MD, PhD2, and Yangsoo Jang, MD, PhD2

1Department of Cardiology, Sanggye-Paik Hospital, Inje University College of Medicine, Seoul, Korea
2Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea
3Department of Cardiology, Myeongji Hospital, Goyang, Korea
4Cardiovascular & Arrhythmia Center, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea

ABSTRACT

Background and Objectives: The effectiveness of angiotensin II receptor blockers (ARBs) compared with angiotensin converting enzyme inhibitors (ACEIs) in patients with acute myocardial infarction (AMI) has not been established. We investigated the effects of ARBs on clinical outcomes after percutaneous coronary intervention (PCI) in AMI patients.

Methods: Patients receiving ACEIs or ARBs after AMI treated with PCI between January 2005 and December 2014 were selected from the Korean National Health Insurance Service database. The primary endpoint was major cardiovascular adverse event (MACE; all-cause death, myocardial infarct [MI], or stroke).

Results: We included patients regularly taking ACEIs (n=22,331) or ARBs (n=28,533) (medication possession ratio ≥80%). Compared with the ACEI group, the ARB group contained more females (31% vs. 18%), were older (mean, 63 vs. 60 years), and had more comorbidities, including hypertension (62.8% vs. 44.8%), diabetes (33.9% vs. 26.4%), congestive heart failure (7.9% vs. 4.3%), chronic obstructive pulmonary disease (25.5% vs. 18.9%), and end-stage renal disease (1.3% vs. 0.4%) (p<0.001 for all). After propensity score–matching, ARBs were associated with a 23% lower risk of MACE (hazard ratio [HR], 0.774; 95% confidence interval [CI], 0.715–0.838; p<0.001) than ACEIs. ARB use was also associated with a significantly reduced risk of death (HR, 0.741; 95% CI, 0.659–0.834; p<0.001), MI (HR, 0.731; 95% CI, 0.638–0.837; p<0.001), and revascularization (HR, 0.816; 95% CI, 0.773–0.861; p<0.001).

Conclusions: ARB use was associated with a lower risk of MACE, MI, and revascularization than ACEIs in our retrospective analysis of AMI patients who underwent PCI.
INTRODUCTION

Chronic activation of the renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathogenesis of cardiovascular diseases, and inhibition of RAAS reduces cardiovascular mortality and morbidity across a wide spectrum of cardiovascular disorders. Specifically, increased angiotensin II levels after myocardial infarction (MI) exert adverse cardiovascular effects through vasoconstriction, fluid retention, sympathetic nerve system activation, platelet activation, and myocardial remodeling.

RAAS blockade is accomplished therapeutically by two main groups of medications that have different pharmacologic actions: angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). ACEIs suppress not only the production of angiotensin, but also prevent the breakdown of bradykinin, thereby inducing additional cardioprotective effects. In contrast, ARBs reduce RAAS activity by selective inhibition of angiotensin II receptors.

Use of ACEIs after MI has been demonstrated to slow the progression of heart failure and reduce the occurrence of cardiovascular events. International guidelines recommend early use of ACEIs after an acute myocardial infarction (AMI), especially in patients with heart failure, hypertension, diabetes, or ST segment elevation MI. However, ACEIs may produce cough, altered taste, or rash leading to dose reduction or permanent discontinuation of the medication, and drug discontinuation is more frequent with these drugs than with ARBs. ACEI intolerance is especially common in Asians, occurring in up to 20% of patients.

ARBs are currently recommended for patients intolerant to ACEI therapy. In two randomized controlled trials, ARBs and ACEIs exhibited similar efficacy for the prevention of death and cardiovascular sorabilities after AMI. However, clinical evidence in support of the use of ARBs in patients with AMI remains limited. In the present study, we used claims data from the Korean National Health Insurance Service (KNHIS) to compare clinical outcomes in real-world practice between the use of ARBs or ACEIs after AMI in patients who underwent percutaneous coronary intervention (PCI) with stent insertion.

METHODS

Study population

This is a retrospective cohort study using claims data from KNHIS, which is the sole insurer of the Korean national health insurance program. KNHIS operates a medical claims database that includes diagnoses, treatments, pharmaceuticals, and procedures, as well as personal data, such as age, sex, residential area, and date of death. All medical service providers and people seeking medical services in Korea are required by national acts to join the KNHIS insurance program. Therefore, the KNHIS database covers almost all medical services performed in the Korean population since 2002. The database is based on the
Korean Standard Classification of Disease-7 coding system, which is compatible with the International Classification of Diseases-10 coding system.

For the present study, we included all patients in the KNHIS database who underwent PCI using a bare metal stent or drug-eluting stent (DES) from 2005 to 2014 while admitted to a hospital under new diagnosis of AMI (diagnostic codes: I21, I22, or I23). The exclusion criteria were coronary bypass surgery, PCI without stent insertion, cardiopulmonary resuscitation, in-hospital death during the index admission, or the presence of metastatic cancer. We also excluded patients who received no antiplatelet agents after the index PCI to minimize confounding factors. The study population was followed after stent implantation for 2 years or until the primary end point occurred.

Data collection and outcome assessments
Data were collected by analyzing diagnostic, prescription, and procedural codes in the claims database. We calculated the medication possession ratio (MPR) by dividing the sum of days for which a medication was prescribed by the number of follow-up days. We classified the study population as regular medication users (MPR ≥80%), irregular medication users (MPR 1%–79%), or non-users (MPR 0%). Only regular users of the respective medications were included in the outcome comparisons between the ARB and ACEI groups. Patients receiving both ACEIs and ARBs and those who changed medications from 1 group to the other during follow-up were excluded from the clinical outcomes comparisons. We defined the index time point as the date of admission for the procedure.

The primary end point was major adverse cardiovascular event (MACE), defined as the composite of all-cause death, myocardial infarction, or stroke (all types). MI was considered to have recurred during follow-up if the main diagnosis of AMI (diagnostic codes: I21, I22, or I23) was combined with rehospitalization and coronary angiography (procedure code: HA670) or if a new diagnosis of sudden cardiac arrest (diagnostic code: I469) was confirmed. We adopted this narrow definition of AMI to avoid misdiagnosis of a previous MI as a new event during follow-up. Strokes included ischemic stroke, hemorrhagic stroke, or unknown type of stroke (diagnostic codes: I60, I61, I62, I63, or I64) that were confirmed with an imaging study (examination codes: HE101, 201, 135, 235, 236, 451, or 461) during hospitalization.

Statistical analysis
χ² tests or Fisher’s exact tests were used to compare categorical variables; Student’s t-tests were used to compare continuous variables. Univariate and distributional analyses included measures of clinical outcomes. For propensity-score matching, we performed 1:1 case-control matching based on the propensity score with a hierarchical sequence until there were no more further matches. SAS logistic procedure code was used to create the propensity scores. The variables included in the propensity score matching were following confounding factors: age, sex, year of study enrollment, hypertension, diabetes mellitus, dyslipidemia, previous stroke, previous MI, heart failure, history of malignancy, stent type, number of stents, and in-hospital and follow-up medications (dual antiplatelet agents, beta blockers, calcium channel blockers, statins, loop diuretics, and spironolactone). Cox proportional-hazards regression analysis was used to assess the effects of ACEIs or ARBs as independent predictors of MACE. Statistical analysis was performed using SAS software (SAS Institute, Ver 9.1, Cary, NC, USA). The statistical significance level was set at p<0.05.
RESULTS

Baseline characteristics
We identified a total of 108,728 patients who met the study inclusion criteria from January 2005 to December 2014. Of these, 84,260 (77.5%) patients were prescribed one or more RAAS blockers at hospital discharge and 68,459 (62.96%) patients were regular RAAS blocker users during the 2-year follow-up period (Figure 1). After excluding 17,595 patients who were prescribed both ARBs and ACEIs or who converted from an ARB to an ACEI or from an ACEI to an ARB during follow-up, we enrolled 50,864 regular users of either an ARB (n=28,533) or an ACEI (n=22,331) in this study.

Overall, the mean age of the study population was 62 years, and 74% of the included patients were male. Baseline characteristics, implanted stents, and prescribed medications for the two patient groups are summarized in Table 1. Compared with the ACEI group, the ARB group contained more females (31% vs. 18%, p<0.001) and was older (mean age, 63 years vs. 60 years, p<0.001). In addition, several comorbidities were more frequent in the ARB group than in the ACEI group: hypertension (62.8% vs. 44.8%, p<0.001), DM (33.9% vs. 26.4%, p<0.001), CHF (7.9% vs. 4.3%, p<0.001), chronic obstructive pulmonary disease (25.5% vs. 18.9%, p<0.001), and end-stage renal disease (1.3% vs. 0.4%, p<0.001) (Table 1).

After performing propensity-score matching for the entire population, we obtained 19,762 matched pairs of ARB users and ACEI users (Table 2). Standardized differences between propensity-matched groups were <0.1 for all baseline characteristics and medications. The ARBs and ACEIs prescribed for the study population were presented in Supplementary Table 1.
Clinical outcomes

In non-matched comparisons, the ARB and ACEI groups had similar rates of MACE (6.5% vs. 6.8%, hazard ratio [HR], 0.947; 95% confidence interval [CI], 0.885–1.014), as well as individual clinical events, including all-cause death, MI, stroke, and revascularization (Table 3).

However, in matched comparisons, the ARB group had a 23% lower risk of MACE (HR, 0.770; 95% CI, 0.711–0.834; p<0.001), compared with the ACEI group. The ARB group also had significantly lower risks of all-cause death (HR, 0.743; 95% CI, 0.66–0.835; p<0.001), MI (HR, 0.727; 95% CI, 0.635–0.833; p<0.001), and revascularization (HR, 0.821; 95% CI, 0.759–0.845; p<0.001) (Table 4).

In a Cox proportional hazard multivariate regression model, ARB was identified as an independent protective factor for MACE (HR, 0.781; 95% CI, 0.727–0.839; p<0.0001) (Table 5). Other determinants for MACE were age, male gender, hypertension, diabetes, dyslipidemia, previous stroke, congestive heart failure, chronic obstructive pulmonary disease, end stage renal disease, history of malignancy, bare metal stent, 1st generation drug-eluting stent, number of implanted stents ≥2, dual antiplatelet agents, non-use of antiplatelet agent, use of statin, loop diuretics, aldactone, and vasodilators.

Table 1. Baseline characteristics of ACEI or ARB users

| Characteristic                          | ARB group (n=28,533) | ACEI group (n=22,331) | p     |
|-----------------------------------------|----------------------|-----------------------|-------|
| Age (years)                             | 63±12                | 60±12                 | <0.001|
| Male                                    | 19,711 (69.1)        | 18,408 (82.4)         | <0.001|
| Study enrollment                        |                      |                       |       |
| 2005–2008                               | 8,411 (29.5)         | 8,610 (38.6)          |       |
| 2009–2011                               | 8,786 (30.8)         | 6,702 (30.0)          |       |
| 2012–2014                               | 11,336 (39.7)        | 7,019 (31.4)          |       |
| Comorbidities                           |                      |                       |       |
| Hypertension                            | 17,915 (62.8)        | 10,012 (44.8)         | <0.001|
| DM                                      | 9,667 (33.9)         | 5,891 (26.4)          | <0.001|
| Dyslipidemia                            | 9,617 (33.7)         | 5,626 (25.2)          | <0.001|
| Previous stroke                         | 2,884 (10.1)         | 1,595 (7.1)           | <0.001|
| CHF                                     | 2,255 (7.9)          | 948 (4.3)             | <0.001|
| COPD                                    | 7,278 (25.5)         | 4,216 (18.9)          | <0.001|
| ESRD                                    | 372 (1.3)            | 84 (0.4)              | <0.001|
| History of malignancy                   | 934 (3.3)            | 658 (2.9)             | 0.036 |
| Type of stent                           |                      |                       | <0.001|
| BMS                                     | 1,025 (3.6)          | 1,247 (5.6)           |       |
| 1st generation DES                      | 7,329 (25.7)         | 6,957 (31.2)          |       |
| 2nd generation DES                      | 20,179 (70.7)        | 14,127 (63.3)         |       |
| Number of stents                        | 0.725                |                       |       |
| 1                                       | 23,485 (82.3)        | 18,407 (82.4)         |       |
| 2 or more                               | 5,048 (17.7)         | 3,924 (17.6)          |       |
| Medications during follow-up            |                      |                       |       |
| Dual antiplatelet agents (aspirin plus clopidogrel) | 17,077 (59.9)        | 13,554 (60.7)         | <0.001|
| Aspirin only                            | 7,827 (27.4)         | 6,295 (28.2)          |       |
| Clopidogrel only                        | 3,312 (11.6)         | 2,310 (10.3)          |       |
| Beta blocker                            | 20,291 (71.1)        | 17,619 (78.9)         | <0.001|
| Statin                                  | 24,381 (85.5)        | 19,237 (86.1)         | 0.026 |
| Loop diuretic                           | 3,564 (12.5)         | 2,322 (10.4)          | <0.001|
| Aldactone                               | 1,606 (5.6)          | 1,432 (6.4)           | 0.002 |
| Vasodilator                             | 9,753 (34.2)         | 8,040 (36.0)          | 0.002 |
| Number of antihypertensives             | 1.93±0.63            | 1.86±0.49             | <0.001|

Values are expressed as number (%), or mean±standard deviation.

ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor II blocker; BMS = bare metal stent; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; DES = drug-eluting stent; DM = diabetes mellitus; ESRD = end-stage renal disease; SD = standard deviation.
In this retrospective study using KNHIS claims data, we found that patients with AMI treated with PCI were more frequently prescribed ARBs than ACEIs. Furthermore, patients treated with ARBs had significantly lower rates of adverse clinical events, including MACE, all-cause death, MI, and revascularization, than those treated with ACEIs.

Table 2. Baseline characteristics of ACEI or ARB users after propensity-score matching

| Characteristic                  | ARB group (n=19,762) | ACEI group (n=19,762) | SD       | p       |
|--------------------------------|----------------------|-----------------------|----------|---------|
| Age (years)                    | 61±12                | 61±12                 | 0.00     | <0.001  |
| Male                           | 15,960 (80.7)        | 15,872 (80.3)         | −0.01    | <0.001  |
| Study enrollment               |                      |                       | 0.581    |         |
| 2005–2008                      | 6,842 (34.6)         | 6,886 (34.8)          | 0.00     |         |
| 2009–2011                      | 6,045 (30.6)         | 6,099 (30.9)          | 0.00     |         |
| 2012–2014                      | 6,875 (34.8)         | 6,777 (34.3)          | −0.01    |         |
| Comorbidities                  |                      |                       |          |         |
| Hypertension                   | 9,901 (50.1)         | 9,829 (49.7)          | −0.01    | 0.820   |
| DM                             | 5,526 (27.9)         | 5,574 (28.2)          | 0.00     | <0.001  |
| Dyslipidemia                   | 5,360 (27.1)         | 5,402 (27.3)          | 0.00     | <0.001  |
| Previous stroke                | 1,509 (7.6)          | 1,545 (7.8)           | 0.01     | <0.001  |
| CHF                            | 912 (4.6)            | 937 (4.7)             | 0.01     | <0.001  |
| COPD                           | 3,984 (20.2)         | 4,036 (20.4)          | 0.01     | <0.001  |
| ESRD                           | 76 (0.4)             | 83 (0.4)              | 0.01     | <0.001  |
| History of malignancy          | 623 (3.2)            | 613 (3.1)             | 0.00     | <0.001  |
| Type of stent                  |                      |                       | 0.729    |         |
| BMS                            | 859 (4.4)            | 891 (4.5)             | 0.01     |         |
| 1st generation DES             | 5,770 (29.2)         | 5,773 (29.2)          | 0.00     |         |
| 2nd generation DES             | 13,133 (66.5)        | 13,098 (66.3)         | 0.00     |         |
| Number of stents               |                      |                       | <0.001   |         |
| 1                              | 16,380 (82.9)        | 16,303 (82.5)         | −0.01    |         |
| 2 or more                      | 3,382 (17.1)         | 3,459 (17.5)          | 0.01     |         |
| Medications during follow-up   |                      |                       |          |         |
| Dual antiplatelet agents (aspirin plus clopidogrel) | 11,930 (60.4) | 11,880 (60.1) | 0.00 | 0.760   |
| Aspirin only                   | 5,607 (28.4)         | 5,592 (28.3)          | 0.00     |         |
| Clopidogrel only               | 2,057 (10.4)         | 2,123 (10.7)          | 0.01     |         |
| Betablocker                    | 14,821 (75.0)        | 15,019 (76.0)         | 0.00     | <0.001  |
| Statin                         | 17,107 (86.6)        | 17,015 (86.1)         | −0.01    | <0.001  |
| Loop diuretic                  | 2,063 (10.4)         | 2,147 (10.9)          | 0.01     | <0.001  |
| Aldactone                      | 1,173 (5.9)          | 1,198 (6.1)           | 0.00     | <0.001  |
| Vasodilator                    | 6,884 (34.8)         | 6,976 (35.3)          | 0.01     | <0.001  |
| Number of antihypertensives    | 1.8±0.60             | 1.88±0.48             | 0.00     | <0.001  |

Values are expressed as number (%), or mean±standard deviation.
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor II blocker; BMS = bare metal stent; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; DES = drug-eluting stent; DM = diabetes mellitus; ESRD = end-stage renal disease; SD = standard deviation.

Table 3. Number of events after percutaneous coronary intervention with stent insertion in patients with acute MI before propensity-score matching

| Clinical events | ARB group (n=28,533) | ACEI group (n=22,331) | Hazard ratio (95% CI)* |
|-----------------|----------------------|-----------------------|------------------------|
| MACE            | 1,870 (6.5)          | 1,513 (6.8)           | 0.947 (0.885–1.014)    |
| All-cause death | 937 (3.3)            | 682 (3.1)             | 1.052 (0.953–1.161)    |
| MI              | 554 (1.9)            | 577 (2.6)             | 0.737 (0.656–0.828)    |
| Stroke          | 431 (1.5)            | 299 (1.3)             | 1.105 (0.953–1.280)    |
| MI or stroke    | 980 (3.4)            | 873 (3.9)             | 0.861 (0.786–0.943)    |
| Revascularization | 3,409 (12.2)      | 3,376 (15.1)          | 0.772 (0.736–0.809)    |

Values are expressed number (%).
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor II blocker; CI = confidence interval; MACE = major adverse cardiovascular event; MI = myocardial infarction.
*Compared with ACEI as the reference.

DISCUSSION

In this retrospective study using KNHIS claims data, we found that patients with AMI treated with PCI were more frequently prescribed ARBs than ACEIs. Furthermore, patients treated with ARBs had significantly lower rates of adverse clinical events, including MACE, all-cause death, MI, and revascularization, than those treated with ACEIs.
Although both ARBs and ACEIs modulate the RAAS, these drugs have different action mechanisms which may lead to different effects on cardiovascular outcomes in AMI patients. ACEIs not only block the conversion of angiotensin I to angiotensin II but also

### Table 4. Clinical outcomes after propensity score matching

| Clinical events | ARB Patients-year | 2-year predicted event rate | ACEI Patients-year | 2-year predicted event rate | HR of ARB | 95% CI | p     |
|-----------------|-------------------|-----------------------------|-------------------|-----------------------------|-----------|--------|-------|
| MACE            | 3,146.1           | 0.06                        | 4,076.6           | 0.08                        | 0.774     | 0.715–0.838 | <0.0001 |
| All death       | 1,420.8           | 0.03                        | 1,917.3           | 0.04                        | 0.741     | 0.659–0.834 | <0.0001 |
| MI              | 1,061.3           | 0.02                        | 1,460.4           | 0.03                        | 0.711     | 0.638–0.837 | <0.0001 |
| Stroke          | 742.3             | 0.01                        | 832.2             | 0.02                        | 0.894     | 0.754–1.059 | 0.1949  |
| MI or stroke    | 1,794.9           | 0.03                        | 2,284.7           | 0.04                        | 0.789     | 0.71–0.877  | <0.0001 |
| Revascularization | 7,718.7           | 0.13                        | 8,753.5           | 0.15                        | 0.816     | 0.773–0.861 | <0.0001 |
| All rehospitalization | 23,762.7     | 0.46                        | 24,265.4          | 0.45                        | 0.969     | 0.939–0.999 | 0.0419  |

ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor II blocker; CI = confidence interval; HR = hazard ratio; MACE = major adverse cardiovascular event; MI = myocardial infarction.

*Events at 100 patient years.

### Table 5. Univariate and multivariate predictors of major adverse cardiovascular event after coronary stenting after AMI

| Risk factors | Univariate | Multivariate |
|--------------|------------|--------------|
| **Age** | 1.055 | 1.045 | <0.0001 | 1.045 | 1.042–1.049 | <0.0001 |
| **Male** | 0.636 | 0.593–0.683 | <0.0001 | 1.189 | 1.101–1.285 | <0.0001 |
| **Study enrollment** | | | | | | |
| 2005–2008 | 1 | - | - | 1 | - | - |
| 2009–2011 | 0.809 | 0.746–0.878 | <0.0001 | 1.084 | 0.976–1.204 | 0.1334 |
| 2012–2014 | 0.744 | 0.686–0.807 | <0.0001 | 0.984 | 0.874–1.109 | 0.7944 |
| **Underlying medical condition** | | | | | | |
| Hypertension | 2.003 | 1.861–2.157 | <0.0001 | 1.138 | 1.046–1.239 | 0.0028 |
| DM | 1.826 | 1.706–1.954 | <0.0001 | 1.323 | 1.229–1.425 | <0.0001 |
| Dyslipidemia | 1.182 | 1.1–1.27 | <0.0001 | 0.919 | 0.851–0.992 | 0.0304 |
| Previous stroke | 2.436 | 2.233–2.657 | <0.0001 | 1.484 | 1.355–1.624 | <0.0001 |
| CHF | 2.573 | 2.336–2.835 | <0.0001 | 1.344 | 1.213–1.49 | <0.0001 |
| COPD | 1.678 | 1.568–1.804 | <0.0001 | 1.140 | 1.057–1.228 | 0.0006 |
| ESRD | 5.973 | 5.057–7.054 | <0.0001 | 4.152 | 3.484–4.946 | <0.0001 |
| History of malignancy | 2.117 | 1.842–2.435 | <0.0001 | 1.621 | 1.407–1.869 | <0.0001 |
| **Type of stent** | | | | | | |
| BMS | 1.827 | 1.596–2.091 | <0.0001 | 1.723 | 1.491–1.991 | <0.0001 |
| 1st generation DES | 1.369 | 1.273–1.472 | <0.0001 | 1.390 | 1.157–1.438 | <0.0001 |
| 2nd generation DES | 1 | - | - | 1 | - | - |
| **Number of stents** | | | | | | |
| 1 | 1 | - | - | 1 | - | - |
| ≥2 | 1.025 | 0.938–1.118 | 0.5885 | 0.852 | 0.777–0.934 | 0.0007 |
| **Medication** | | | | | | |
| Dual antiplatelet agents | 4.691 | 4.182–5.262 | <0.0001 | 4.128 | 3.677–4.634 | <0.0001 |
| Clopidogrel only | 1.331 | 1.106–1.6 | 0.0024 | 1.178 | 0.979–1.418 | 0.0835 |
| Aspirin only | 1 | - | - | - | - | - |
| No antiplatelet agents | 4.465 | 3.298–6.046 | <0.0001 | 2.985 | 2.201–4.05 | <0.0001 |
| ARB (compared with ACEI) | 0.947 | 0.885–1.014 | 0.072 | 0.781 | 0.727–0.839 | <0.0001 |
| **Beta blocker** | 0.839 | 0.779–0.904 | <0.0001 | 1.027 | 0.844–1.25 | 0.7888 |
| **CCB** | 0.919 | 0.815–1.037 | 0.3695 | 0.800 | 0.692–0.925 | 0.0026 |
| **Statin** | 0.513 | 0.475–0.555 | <0.0001 | 0.653 | 0.602–0.709 | <0.0001 |
| **Loop diuretics** | 2.745 | 2.54–2.967 | <0.0001 | 1.502 | 1.374–1.641 | <0.0001 |
| **Aldactone** | 2.393 | 2.16–2.651 | <0.0001 | 1.401 | 1.251–1.57 | <0.0001 |
| **Vasodilators** | 1.444 | 1.348–1.545 | <0.0001 | 1.198 | 1.118–1.284 | <0.0001 |

ACEI = angiotensin converting enzyme inhibitor; AMI = acute myocardial infarction; ARB = angiotensin receptor II blocker; BMS = bare metal stent; CCB = calcium channel blocker; CI = confidence interval; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; DES = drug-eluting stent; DM = diabetes mellitus; ESRD = end-stage renal disease; HR = hazard ratio.

https://e-kcj.org
https://doi.org/10.4070/kcj.2020.0057
990
the degradation of bradykinin by inhibition of angiotensin-converting enzyme.\textsuperscript{12} Thereby, ACEIs decrease the formation of angiotensin II, a potent vasopressor, but increase the level of bradykinin, a vasodilator. However, long-term treatment with ACEIs leads to a gradual rise of circulating angiotensin II concentration to pretreatment levels, a phenomenon described as “angiotensin II escape.”\textsuperscript{14} Angiotensin II production by other enzymes in the tissues may be responsible for this phenomenon. In contrast, ARBs directly target on the angiotensin type 1 receptor (AT1R).\textsuperscript{15} The selective action on the attenuated total internal reflection leads to unopposed stimulation of angiotensin type 2 receptor, which in turn counteracts the vasoconstrictive effects due to AT1R stimulation.\textsuperscript{18} However, ARBs bypass the bradykinin pathway and may lack potential cardiovascular protective effects of bradykinin. On the other hand, ARBs do not induce cough or angioedema by accumulation of bradykinin.\textsuperscript{16}

Recent meta-analyses demonstrated that ACEIs and ARBs have similar effectiveness for preventing major cardiovascular outcomes, such as AMI, stroke, and heart failure or hospitalization, although ACEIs are more effective for reducing total deaths and cardiovascular deaths.\textsuperscript{17-20} However, only 2 randomized controlled trials have compared ARBs versus ACEIs for preventing mortality and morbidity after AMI.\textsuperscript{10,12} The Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL),\textsuperscript{11} which compared losartan with captopril in patients with AMI and symptoms of heart failure or left ventricular dysfunction, found no significant differences between the 2 drugs for all-cause mortality and cardiovascular events, although there was a trend towards lower mortality in the captopril group. In the Valsartan in Acute Myocardial Infarction (VALIANT) trial,\textsuperscript{12} which compared valsartan with captopril in patients with heart failure or left ventricular systolic dysfunction after AMI, valsartan was non-inferior to captopril with regard to total mortality and fatal or non-fatal adverse cardiovascular events. Based on these trials, current guidelines recommend ACEIs as first-choice treatment after AMI in patients with heart failure and/or left ventricular dysfunction, with ARBs considered an alternative for ACEI-intolerant patients.\textsuperscript{9,10,20} However, these trials were conducted in the early 2000s; reperfusion therapy was performed in only approximately 10% and 30% of subjects in the OPTIMAAL\textsuperscript{11} and VALIANT\textsuperscript{12} trials, respectively; and the statin prescription rate was only 30%. Thus, these trials may not reflect contemporary clinical practice for the treatment of AMI.

In recent years, several retrospective cohort studies comparing ARB and ACEI use after AMI reported inconsistent results. Hara et al. found that ACEIs were associated with better survival than ARBs.\textsuperscript{22} Similarly, Korean investigators such as Ann et al.\textsuperscript{23} and Choi et al.\textsuperscript{24} also demonstrated improved survival with ACEIs. By contrast, Lee et al.\textsuperscript{25} reported that ARBs were superior to ACEIs for preventing in-hospital mortality and 12-month MACE, findings compatible with our study results. Other Korean data by Yang et al.\textsuperscript{26} showed comparable effectiveness of ARBs and ACEIs. Unlike the randomized controlled trials, these cohort studies included patients both with and without heart failure or left ventricular dysfunction after AMI.\textsuperscript{19,22-26} The percentages of patients with heart failure or Killip class II/IV in these cohort studies ranged from 2.2% to 18.1%. In the present study, approximately 6% of enrolled patients had congestive heart failure. Thus, the results of the cohort studies cannot be directly compared with those of the randomized control trials. A recent meta-analysis reported that ARBs effectively reduce cardiovascular mortality and morbidity in patients without heart failure; although studied in a non-AMI setting,\textsuperscript{27} these findings are consistent with the results of our study. Previously, several studies reported increased cardiovascular events in patients treated with ARBs, suggesting the existence of an ARB MI paradox.\textsuperscript{28} We did not observe an increased risk of cardiovascular events with ARB use in the present analysis.
Our study has several strengths. Firstly, it represents data from essentially all patients with an AMI treated with PCI (including stent insertion) in Korea between 2005 and 2014, which included >100,000 patients. This is the largest study population reported so far. Secondly, all clinical events during the follow-up period were captured; collecting data from the KNHIS database minimized loss of outcome information. Thirdly, our study differs from the previous studies in the study design. The previous studies categorized patient groups based on hospital discharge medication. However, in our study, the patient groups were analyzed based on the outpatient prescription for a 2-year follow-up period. Furthermore, this study accounted for treatment compliance by including only patients with an MPR ≥80% when comparing outcomes of ARBs versus ACEIs. No prior cohort study accounted for compliance in their analyses. Ortolani et al. reported that poor adherence to ACEI or ARB prescription medication was associated with a 20% increased risk of recurrent AMI. We further excluded 17,595 patients who received both ACEIs and ARBs during the follow-up period. Among them, 84.3% changed the medication from an ACEI to an ARB. Thus, discharge medication may not represent the actual medication the patients take for long term. In the OPTIMAAL study, ARBs were significantly better tolerated than ACEIs, with fewer patients discontinuing study medication. The relatively high rate of conversion from ACEI to ARB observed in our study likely reflects the previously reported higher rate of ACEI intolerance in Asians.

Our study also has limitations. Firstly, this is a retrospective observational study. The possibility of bias cannot be excluded, despite the use of propensity score–matching to adjust for known potential confounding factors. Secondly, in this study, we included all patients who underwent PCI using stents under new diagnosis of MI. However, since cardiac biomarker or electrocardiogram data were not available, the accuracy of MI diagnosis remains uncertain. Furthermore, MI was considered to have recurred during follow-up if the diagnosis of MI was combined with rehospitalization and coronary angiography or if a new diagnosis of sudden cardiac arrest was confirmed. However, some of these patients might have been rehospitalized and have undergone coronary angiography for reasons other than recurrent MI. Thus, the rate of recurred MI might have been overestimated. Thirdly, we were unable to obtain important laboratory, angiography or echocardiography data. Thus, we could not accurately determine cardiovascular disease status or heart failure severity, although we tried to adjust for left ventricular systolic dysfunction by identifying patients prescribed loop diuretics or spironolactone. In addition, there might have been also other confounding factors that were not included in the KNHIS database. Lastly, we were unable to collect information about the dosage of ACEIs or ARBs, which also may have impact on the clinical outcomes.

In conclusion, ARB use was associated with lower rates of MACE, MI, and revascularization than ACEIs in our retrospective analysis of a large, diverse group of patients with AMI treated with PCI in Korea. Further clinical trials are required to validate our findings.

**SUPPLEMENTARY MATERIAL**

**Supplementary Table 1**
Frequency of ACEIs and ARBs prescribed in the study population

[Click here to view](https://e-kcj.org)
REFERENCES

1. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010;160:1273-92.
PUBMED | CROSSREF

2. Nehme A, Zibara K. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection? Hypertens Res 2017;40:903-9.
PUBMED | CROSSREF

3. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
PUBMED | CROSSREF

4. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
PUBMED

5. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
PUBMED | CROSSREF

6. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8.
PUBMED | CROSSREF

7. Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med 2006;166:787-96.
PUBMED | CROSSREF

8. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006;332:1177-81.
PUBMED | CROSSREF

9. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139-228.
PUBMED | CROSSREF

10. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315.
PUBMED | CROSSREF

11. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.
PUBMED | CROSSREF

12. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
PUBMED | CROSSREF

13. Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence 2013;7:509-16.
PUBMED | CROSSREF

14. Ennezet PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000;2:258-62.
PUBMED | CROSSREF

15. Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol 2013;10:125-34.
PUBMED | CROSSREF
16. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004;10:499-509.
PUBMED | CROSSREF
17. Singh A, Bangalore S. Do angiotensin receptor blockers prevent myocardial infarctions as well as other initial therapies? Curr Opin Cardiol 2012;27:381-5.
PUBMED | CROSSREF
18. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014;174:773-85.
PUBMED | CROSSREF
19. Ricci F, Di Castelnuovo A, Savarese G, Perrone Filardi P, De Caterina R. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis. Int J Cardiol 2016;217:128-34.
PUBMED | CROSSREF
20. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619.
PUBMED | CROSSREF
21. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-140.
PUBMED | CROSSREF
22. Hara M, Sakata Y, Nakatani D, et al. Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker. Am J Cardiol 2014;114:1-8.
PUBMED | CROSSREF
23. Ann SH, Strauss MH, Park GM, et al. Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention. Int J Cardiol 2020;306:35-41.
PUBMED | CROSSREF
24. Choi IS, Park IB, Lee K, et al. Angiotensin-converting enzyme inhibitors provide better long-term survival benefits to patients with AMI than angiotensin II receptor blockers after survival hospital discharge. J Cardiovasc Pharmacol Ther 2019;24:120-9.
PUBMED | CROSSREF
25. Lee JH, Bae MH, Yang DH, et al. Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction. Korean J Intern Med 2016;31:267-76.
PUBMED | CROSSREF
26. Yang JH, Hahn JY, Song YB, et al. Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study. BMJ 2014;349:g6650.
PUBMED | CROSSREF
27. Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013;61:131-42.
PUBMED | CROSSREF
28. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006;114:838-54.
PUBMED | CROSSREF
29. Ortolani P, Di Bartolomeo S, Marino M, et al. Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study. Eur Heart J Cardiovasc Pharmacother 2015;1:254-9.
PUBMED | CROSSREF